Wedbush Securities raises its rating on Norwegian Cruise Line to outperform from neutral, citing positive results from a survey of travel agents. » Read More
By: Arjun Kharpal
Capcom announced the release of "Monster Hunter XX" on the Nintendo Switch, giving investors hope that sales of the console could get a boost. » Read More
These big winners for the Dow added $92 billion in market value to the pockets of investors, USA Today reports.
Jim Cramer points to a red flag when it comes to retirement.
Jim Cramer offered his guide on how to best prepare for your financial future ahead of the New Year.
Jim Lebenthal, who's up 33 percent this year in his CNBC PRO model portfolio, sells Time Warner.
UBS says UnitedHealth and Amazon are the stocks domestic fund managers are most overweight.
It’s complicated, but one trader makes it simple: He’s betting on pre-inauguration volatility.
Some of the names on the move ahead of the open.
The market rally has nothing to do with Donald Trump's win in the U.S. election in November, an analyst told CNBC Tuesday.
Jim Cramer broke down how to identify a best-of-breed company in a sector.
A Wall Street veteran has hiked his earnings forecast for 2017, citing a more business friendly environment under a Trump administration.
A daily look at the morning's key financial stories.
Jim Cramer opens up about mistakes of investing, and his rules for owning individual stocks.
Carl Icahn shares his market views in an interview with CNBC's Scott Wapner.
Jim Cramer explained how his view of the market was forever rocked by the Great Recession.
One trader said the narrative in retail is that Amazon is outperforming the rest of the sector, but its stock performance doesn't necessarily reflect that.
Wall Street has been hoping to end the year with a bang — with the Dow finishing above 20,000.
Tweeting at Lockheed and Boeing won't necessarily lower defense costs much, but it may give Trump more power, some military analysts say.
The stake would make Alden the top shareholder in the company, according to Thomson Reuters data.
Synergy Pharmaceuticals skyrocketed after the firm reported positive trial results for an irritable bowel syndrome drug.
Jim Cramer drilled down on retail's woes and how the Trump administration could cause further pain to the retail cohort.
Get the best of CNBC in your inbox